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Abstract
Background: The degree of ADHD-related difficulties – reflecting overall impairment, social functioning, and quality of
life – may be perceived differently by adolescent patients, parents and physicians. The primary aim of this study was to
investigate ADHD-related difficulties during atomoxetine treatment, as perceived by the three different raters.
Secondary objectives focused on effectiveness and tolerability of atomoxetine treatment in a population of adolescent
patients with ADHD.
Methods: Adolescents with ADHD, aged 12–17 years, received open-label atomoxetine (0.5–1.2 mg/kg/day) up to 24
weeks. ADHD-related difficulties at various times of the day were rated using the Global Impression of Perceived
Difficulties (GIPD) instrument. Inter-rater agreement was analyzed using Cohen's Kappa with 95% confidence intervals
(95% CI). ADHD-Rating Scale (ADHD-RS) and Clinical Global Impression Severity (GGI-S) scores were assessed by the
investigator; and spontaneous adverse events, vital signs and laboratory parameters were collected for tolerability
assessments.
Results: 159 patients received atomoxetine. Patients' baseline mean GIPD total ratings were significantly lower than
parents' and physicians' scores (12.5 [95%CI 11.6;13.5] vs. 17.2 [16.2;18.2] and 18.8 [17.8;19.8]). For all raters, GIPD
scores significantly improved over time. Changes were greatest within the first two weeks. Kappa coefficients varied
between 0.186 [0.112;0.259] and 0.662 [0.529;0.795], with strongest agreements between parent and physician
assessments, and significant improvements of patient/physician agreements over time (based on 95% CIs). ADHD-RS and
CGI-S scores significantly improved over the course of the study (based on 95% CIs). Tolerability results were consistent
with earlier reports.
Conclusion: ADHD-related difficulties were perceived differently by the raters in this open-label trial, but consistently
improved during atomoxetine treatment. The GIPD instrument appeared sensitive to treatment-related change. These
primarily quantitative findings may guide future studies to more systematically investigate the clinical and practical
relevance of the differences observed. Additionally, in order to further validate these results, placebo- and comparator-
controlled trials are recommended as well as inclusion of healthy controls and other patient populations.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is char-
acterized by inattention, impulsivity, and hyperactivity
and affects 3–7% of school-aged children in the United
States [1]. ADHD is associated with significant impair-
ment of cognitive and psychosocial functioning [2,3] and
quality of life (QoL) in patients and families [4-7].
Beyond the improvement of core symptoms during
ADHD treatment, there is growing appreciation of possi-
ble additional patient and family benefits, including QoL
and functional outcome parameters [8-10].
Atomoxetine is a non-stimulant treatment option for
ADHD [11,12], efficacy and tolerability in children and
adolescents have been demonstrated in a number of pla-
cebo-controlled randomized clinical trials [8,10,13-16],
supported by various meta-analyses [17-20]. These studies
have primarily used investigator-rated questionnaires
such as the ADHD Rating Scale (ADHD-RS) [21,22] and
the Clinical Global Impression (CGI) [23,24] as outcome
measures for the core symptoms of ADHD. Other ques-
tionnaires, such as the Child Health Questionnaire
(CHQ) [25] and Child Health and Illness Profile – Child
Edition (CHIP-CE) [26] assess aspects of ADHD that go
beyond the core symptoms of the disorder and reflect var-
ious dimensions of health-related QoL. To date, several
studies have shown improvement in health-related QoL
of children and adolescents treated with atomoxetine
[8,9,27-31].
However, when assessing QoL in adolescents with ADHD,
both, symptom severity and ADHD-related difficulties,
may be perceived and rated differently by patients, par-
ents, and physicians [7]. For example, children and ado-
lescents may perceive and rate the difficulties associated
with ADHD as less severe than their parents do [32].
Health-related QoL is a multidimensional concept that
reflects the subjective physical, social and psychological
aspects of health and is distinct from symptoms of the dis-
order and objective functional outcomes [33]. QoL
closely depends on the subjectively perceived impact of
the disorder (and of the respective treatment) on the level
of physical, psychological and social functioning [34,35].
The severity of difficulties related to the disorder as per-
ceived by the patients may therefore be considered a good
indicator reflecting QoL, beyond the symptoms assessed
on the various scales based on the diagnostic items from
the DSM-IV [e.g., [21,22]] This patient perspective may be
compared with the perspectives of parents and physicians.
Also, symptoms (e.g., inattention) of the disorder itself
may contribute to altered perceptions of those difficulties
by the patient.
Thus, the primary objective of this study was to investi-
gate the severity of ADHD-related difficulties perceived by
patients, parents, and physicians during atomoxetine
treatment, and to compare these three perspectives over
the course of the study, using the Global Impression of
Perceived Difficulties (GIPD) instrument. The psychomet-
ric properties of this brief scale have recently been
reported [36]; it has especially been devised to capture the
perception of the patient's ADHD-related difficulties from
a patient, parent, and physician perspective (with adjusted
wording for each). The GIPD instrument can be consid-
ered to reflect overall impairment, psychosocial function-
ing, and quality of life (QoL); sensitivity to treatment-
related change over time has also been indicated [37]. It
consists of five items which assess ADHD-related difficul-
ties at the typical situations over the course of the day
when ADHD patients face their main problems. Each item
is rated on a seven-point scale.
As German ethic committees tend to be rather reluctant
towards placebo-controlled studies in juvenile patients,
and efficacy was not a main objective in this post-launch
study, we decided on a single-arm, open-label design for
reasons of feasibility.
Secondary objectives were to evaluate the effectiveness
and tolerability of atomoxetine in adolescents with
ADHD. Results from a parallel study performed in chil-
dren with ADHD (6 – 11 years of age) have been pub-
lished [37].
Methods
Study design and procedures
This multicenter, open-label, single-arm study was
designed to investigate the degree of ADHD-related diffi-
culties in adolescents with ADHD treated with atomoxet-
ine as perceived by patients, parents, and physicians.
Patients were recruited at 35 child and adolescent psychi-
atry and pediatric practices and outpatient clinics
throughout Germany. Boys and girls aged 12–17 years
with ADHD as defined in DSM-IV-TR were eligible for the
study. The diagnosis was confirmed using the "Diagnose-
Checkliste Hyperkinetische Störungen" (Diagnostic
Checklist for Hyperkinetic Disorders), a structured stand-
ard instrument based on the respective DSM-IV-TR and
ICD-10 criteria [38,39] which is routinely used for diag-
nostic assessment of ADHD in Germany. Comorbid psy-
chiatric and somatic disorders were assessed as part of a
careful clinical examination performed by the investiga-
tors (board-certified child and adolescent psychiatrists or
pediatricians).
Patients were to have an IQ of ≥70 based on the clinical
judgment of the investigator. The exclusion criteria com-
prised significantly abnormal laboratory findings, acuteChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
Page 3 of 15
(page number not for citation purposes)
or unstable medical conditions, cardiovascular disorder,
history of seizures, pervasive developmental disorder, psy-
chosis, bipolar disorder, suicidal ideation, any medical
condition that might increase sympathetic nervous system
activity, or the need for psychotropic medication other
than study drug. Patients already being treated with atom-
oxetine were also excluded. The protocol was approved by
the ethics committee of the University of Cologne, Ger-
many, and the study was conducted in accordance with
the principles of the Declaration of Helsinki.
Following a wash-out period, baseline assessments were
carried out with all the instruments used. During the first
week, the patients were treated with atomoxetine at a dose
of approximately 0.5 mg/kg per day. During the following
7 weeks, the recommended atomoxetine dose was 1.2 mg/
kg per day, which could be adjusted within a range of 0.5
– 1.4 mg/kg per day, depending on effectiveness and tol-
erability. Medication was given once-a-day in the morn-
ing. Assessments were carried out weekly during the first
two weeks of treatment, and every two weeks thereafter.
After the 8-week treatment period, the physicians decided
in accordance with the patients and their parents whether
the patient was going to continue treatment for further 16
weeks, considering both effectiveness and tolerability/
safety of the compound for the respective patient. Patients
who participated in this extension period continued on
the same atomoxetine dose which again could be adjusted
within a range of 0.5 – 1.4 mg/kg per day if necessary.
During the extension period, three assessments were car-
ried out at 12, 16, and 24 weeks after baseline.
The Global Impression of Perceived Difficulties (GIPD)
instrument was used as the primary outcome measure.
The GIPD is a validated instrument [36] that has espe-
cially been developed to capture the perception of the
patient's ADHD-related difficulties from a patient, parent
(or primary caregiver), and physician perspective, and can
be considered to reflect overall impairment, psychosocial
functioning, and quality of life (QoL) [37]. The GIPD con-
sists of five items which assess ADHD-related difficulties
at the typical times of the day, when ADHD patients face
their main problems: (1) in the morning, (2) during
school, (3) during homework, (4) in the evening, and (5)
overall difficulties over the entire day and night. Each item
is rated on a seven-point scale (1 = not at all difficult, 7 =
extremely difficult) in analogy to the CGI-Severity scoring
[23,24], and reflects the situation during the previous
week. There are three different versions with adjusted
wording for each rater, allowing comparisons. The GIPD
Total score was calculated for each rater group by summa-
tion of item scores (range 5 to 35). If one item was miss-
ing, the total score was also considered as missing. The
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-
Parent Version: Investigator-Administered and Scored
(ADHD-RS-IV-Parent:Inv) is an 18-item scale, with one
item for each of the 18 ADHD symptoms listed in DSM-
IV-TR [21,22]. There are 2 subscales: the "hyperactivity/
impulsivity" subscale is the sum of the even items, and the
"inattention" subscale is the sum of the odd items. This
scale is scored by an investigator while interviewing the
parent or primary caregiver.
The Clinical Global Impression-Severity-Attention-Defi-
cit/Hyperactivity Disorder Scale (CGI-S-ADHD) is a seven
point single-item rating scale of the physician's assess-
ment of the severity of ADHD symptoms [23,24].
Following the clinical interview with patients and parents,
and the completion of ADHD-RS-IV and CGI-S-ADHD
scales by the investigator, GIPD ratings were done inde-
pendently by patients and parents during each office visit.
The investigator would then score the GIPD physician ver-
sion taking into account the patient and parent GIPD
scorings from the respective visit plus all additional infor-
mation about the patient provided to him. Adverse event
assessment concluded the session. Thus, GIPD ratings
from patients and parents were not used to inform
ADHD-RS or CGI-S ratings by the investigator or to guide
treatment decisions, e.g., dose-adjustments. Given the
open-label design of the study, this sequence was also
chosen to resemble the routine (naturalistic) course of an
office visit.
Sample size and statistical analysis
For calculating an appropriate sample size, we assumed
that the true value of Kappa [40] for the GIPD scale is 0.8
(between patients and parents as well as between patients
and physicians). The respective two-sided 95% confi-
dence intervals were intended to extend 0.1 from the
observed value of Kappa for the estimate to be sufficiently
precise. Furthermore, we assumed a true response rate of
50%. Thus, a sample size of 139 patients was considered
sufficient for the desired precision. Assuming a propor-
tion of 5% of patients with unspecified data on the GIPD
scale, a sample size of 147 patients was planned.
The data of all patients were evaluated (Full Analysis Set,
FAS). The dataset for all analyses of changes from baseline
to endpoint consisted of all patients with a baseline meas-
urement and at least one post-baseline measurement dur-
ing the 8-week treatment period.
In addition to Last Observation Carried Forward (LOCF)
analyses and Observed Cases (OC) analyses, LOCF-BR
(LOCF – baseline rater) and OC-BR (OC – baseline rater)
analyses were applied: Values not rated by the same indi-
vidual both at baseline and later on (e. g., father rated at
baseline, mother rated later) were replaced by the last
value from the baseline rater (if present), otherwise theChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
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value was deleted. Obviously, this applied only to the par-
ent rating scales.
Evaluation was largely descriptive. All tests of statistical
significance were carried out at a nominal level of 5%
using two-tailed test procedures. Two-sided confidence
intervals (CIs) were computed using a 95% confidence
level. Cohen's weighted Kappa (Kappa) with 95% confi-
dence intervals [40] was used to determine the agreement
between patients and parents, patients and physicians,
and between parents and physicians. Kappa-calculations
were based on OC values and OC-BR for parents, respec-
tively. All other tables and scores cited in the text represent
LOCF values (LOCF-BR for GIPD parent ratings, respec-
tively) whilst the figures are based on OC values. Sub-
group analyses were performed for ADHD-subtypes
(DSM-IV-TR criteria).
Results
Patient population and disposition
Of the 160 patients screened, 159 patients (100%) were
enrolled in the study and treated with atomoxetine, 137
(86.2%) patients completed the treatment period and
continued into the extension period. 20 (12.6%) patients
discontinued early over the course of the 8 week treatment
period, two more (1.3%) completed the treatment period,
but did not continue into the extension period based on
the decision of the physician. 26 (16.4%) patients discon-
tinued between weeks 8 and 24. 111 (69.8%) patients
completed the study at week 24. Discontinuations were
mostly due to lack of efficacy. All reasons for discontinua-
tion are shown in Figure 1.
Table 1 shows the patient characteristics. Male patients
and those with the combined subtype of ADHD appeared
to be younger and to be diagnosed earlier than girls or
patients with the predominantly inattentive subtype. 68
(54.4%) boys and 13 (38.2%) girls were diagnosed with
the combined subtype. The predominantly inattentive
subtype was diagnosed in 53 (42.4%) boys and 20
(58.8%) girls.
Consisting of only 5 subjects, the subgroup of patients
with ADHD, not otherwise specified (NOS) was too small
for further detailed subgroup analyses. There were no
patients meeting criteria for the predominantly hyperac-
tive-impulsive subtype. For the entire patient sample, the
mean time span between first occurrence of symptoms
(parent report) and first professional diagnosis amounted
to approximately 5.5 years.
137 (86.2%) of the 159 adolescents had previously been
treated for ADHD. The percentages of pretreated patients
differed slightly with respect to sex (boys: N = 109, 87.2%,
girls: N = 28, 82.4%) or ADHD-subtype (combined sub-
type N = 67, 82.7%, predominantly inattentive subtype N
= 65, 89.0%). Most frequently used compounds had been
short-acting methylphenidate (N = 119, 74.8%), long-act-
ing methylphenidate (N = 92, 57.9%), amphetamines (N
= 17, 10.7%), and antidepressants (N = 7, 4.4%). Com-
monly reported non-drug therapies prior to study start
were: structured psychotherapy (N = 22, 13.8%), occupa-
tional therapy (N = 11, 6.9%), and other forms of psycho-
therapy (N = 10, 6.3%). The most frequent reason for
discontinuation of any previous therapy was inadequate
response (N = 88, 64.2%).
At baseline, patients (N = 155–158) were rated with the
following mean scores (± SD): GIPD Total: patient 12.5 (±
5.8), parent 17.2 (± 6.3), physician 18.8 (± 6.0); ADHD-
RS-IV: 28.4 (± 10.1), and CGI-S-ADHD: 4.8 (± 0.9).
The mean atomoxetine dose (± SD) given during the first
week of treatment was 0.51 (± 0.06) mg/kg per day (min-
imum 0.40, maximum 0.60 mg/kg per day). Thereafter,
the mean dose ranged between 1.17 and 1.19 mg/kg per
day (minimum 0.40, maximum 1.40 mg/kg per day).
With respect to ADHD-subtype or sex, mean doses were
largely within the same range. Overall compliance was at
Patient disposition Figure 1
Patient disposition.
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least 96.5% over the entire course of the study according
to investigator assessment.
Concomitant medication was taken by 99 (62.3%) of the
patients. Analgesics (N = 37, 23.3%), cough and cold rem-
edies (N = 22, 13.8%), antibiotics (N = 18, 11.3%), phy-
totherapeutics (N = 14, 8.8%; herbal remedies to treat
common colds and upper respiratory tract infections),
and medications for gastrointestinal diseases (N = 7,
4.4%) were reported most frequently. Continuous behav-
iour therapy (ongoing before study start) was applied in
10 (N = 6.3%) patients, and 2 (1.3%) patients received
occupational therapy. Pre-existing concomitant condi-
tions were reported for 105 (66.0%) patients, the most
frequent being psychiatric comorbidities, i.e., conduct dis-
order (N = 29, 18.2%), oppositional defiant disorder (N =
21, 13.2%), emotional disorder of childhood (N = 4,
2.5%). Two patients had depressed mood (N = 2, 1.3%),
Table 1: Patient characteristics
N % Age (years) Height (cm) Weight (kg) Age at start of 
symptoms (years)
Age at ADHD diagnosis 
(years)
Mean SD Mean SD Mean SD Mean SD Mean SD
All patients 159 100 14.1 1.53 163 10.96 54.4 13.40 4.3 2.21 9.8 2.77
Girls 34 21.4 14.4 1.70 162 8.27 55.3 12.96 4.9 2.50 10.7 2.91
Boys 125 78.6 14.0 1.48 163 11.60 54.2 13.56 4.2 2.11 9.6 2.69
ADHD, combined 
type*
81 50.9 13.9 1.50 161 11.09 53.8 14.41 4.1 2.13 9.5 2.68
ADHD, 
predominantly 
inattentive type*
73 45.9 14.2 1.53 165 10.85 54.3 11.90 4.5 2.03 10.1 2.87
ADHD, NOS* 5 3.1 15.0 1.80 167 4.51 67.2 13.19 6.3 4.58 11.2 2.51
* According to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition™.
SD = Standard Deviation, NOS = not otherwise specified
Table 2: Global Impression of Perceived Difficulties (GIPD) total scores, rated by patients, parents and physicians, by ADHD subtype
GIPD total score
Patient rated Parent rated Physician rated
ADHD subtype N Mean 95% CI N Mean 95% CI N Mean 95% CI
All
Week 0 156 12.5 11.6 – 13.5 155 17.2 16.2 – 18.2 155 18.8 17.8 – 19.8
Week 2 157 10.5 9.6 – 11.4 148 12.6 11.7 – 13.6 158 12.6 11.8 – 13.5
Week 8 158 9.6 8.7 – 10.5 150 11.4 10.5 – 12.4 158 11.0 10.2 – 11.9
Week 24 158 9.9 8.9 – 10.9 153 11.7 10.7 – 12.7 158 12.1 11.0 – 13.1
Combined type
Week 0 79 12.6 11.4 – 13.8 79 17.8 16.4 – 19.2 79 19.6 18.3 – 21.0
Week 2 80 10.7 9.4 – 11.9 76 13.4 12.0 – 14.8 81 13.8 12.5 – 15.0
Week 8 81 10.1 8.9 – 11.3 77 11.9 10.7 – 13.2 81 12.4 11.1 – 13.7
Week 24 81 10.0 8.7 – 11.3 77 11.9 10.6 – 13.2 81 12.9 11.4 – 14.3
Predominantly inattentive type
Week 0 72 12.5 11.0 – 14.0 71 16.4 14.9 – 17.9 71 17.9 16.5 – 19.3
Week 2 72 10.1 8.8 – 11.5 67 11.7 10.4 – 13.0 72 11.3 10.3 – 12.3
Week 8 72 9.0 7.7 – 10.3 68 10.7 9.4 – 12.1 72 9.6 8.5 – 10.7
Week 24 72 9.6 8.1 – 11.1 71 11.4 9.9 – 12.8 72 11.2 9.7 – 12.6
Patient and physician ratings based on LOCF (Last Observation Carried Forward), parient ratings are for LOCF-BR (LOCF, Baseline Rater:
Values not rated by the same individual both at baseline and later on (e. g., father rated at baseline, mother rated later) were replaced
by the last value from the baseline rater (if present), otherwise the value was deleted.
CI = Confidence IntervalChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
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none had concomitant anxiety disorder. Physical comor-
bidities reported at a rate of >2% were headache (N = 10,
6.3%), seasonal allergy (N = 9, 5.7%), acne (N = 8, 5.0%),
and asthma and atopic dermatitis (N = 7, 4.4% each).
GIPD: course over time and agreement between 
perspectives
The mean GIPD total scores for the three rater groups
(patients, parents and physicians) took parallel courses
over time (Figure 2a). At baseline, parents rated the
ADHD-related difficulties somewhat less severe than phy-
sicians (not significant; n. s.), but the parent and physi-
cian mean total scores converged as early as week 2, and
overlapped for the remainder of the study (Table 2). Com-
pared to the parent and physician ratings, the adolescents
perceived their difficulties as significantly less severe at
most time points throughout the study, (cf. 95% CIs).
Mean GIPD total scores improved significantly for all
three rater groups from baseline to week 8 and week 24
(cf. 95% CIs).
With respect to GIPD total scores for different ADHD sub-
types (Table 2), parents and physicians at baseline rated
the ADHD-related difficulties of the adolescents with
combined subtype as slightly more severe than the diffi-
culties of the predominantly inattentive subtype (n. s.). In
contrast, there was no difference between the patient rat-
ings of the two ADHD-subtypes.
Table 3 and 4 summarize the course of GIPD subscores for
morning and evening behaviour (Items 1 and 4 of GIPD
total score). Mean values and course over time (Figure 2)
were similar as for the GIPD total score. All respective dif-
ferences between rater groups and ADHD subtypes were
found in the evening scores as well. Regarding the GIPD
morning score, however, patient-rated mean scores over
time were found close to those for parent and physician
ratings after baseline. The patients' evening rating was sig-
nificantly lower than the parents' and physicians' evening
rating between baseline and week 2. Comparing the mean
GIPD morning and evening scores, it was found that
patients generally tended to rate their difficulties in the
evening lower than those in the morning, whereas parents
and physicians tended to perceive evening difficulties as
more severe (physicians significantly at baseline).
The calculation of Cohen's Kappa coefficients for the
GIPD total score (all patients) revealed an overall increase
of agreement between the three rater groups over the
course of the study. This improvement was statistically
significant for the agreement between patients and physi-
cians (cf. 95% CIs, Table 5).
The highest degree of agreement was found between phy-
sicians and parents. Agreement between patients and par-
ents as well as agreement between patients and physicians
were both markedly below the agreement between physi-
cians and parents, with differences in Kappa coefficients
reaching statistical significance at various points in time
throughout the study (cf. 95% CIs).
Largely the same pattern as for the entire sample was
observed in patients with the ADHD combined type,
while patients with the predominantly inattentive ADHD-
subtype displayed a slightly higher degree of agreement
with their parents and physicians (n. s.).
ADHD Rating Scale (ADHD-RS)
During the first two weeks of atomoxetine treatment,
mean total scores for the investigator-rated ADHD-RS
(ADHD-RS-IV-Parent:Inv) significantly decreased from
28.4 [26.8 to 29.9] at baseline to 16.7 [15.0 to 18.3] at
week 2 (mean [95% CI]; LOCF). Total scores were at 12.9
[11.4 to 14.4] by week 8, and at 13.3 [11.7 to 15.0] by the
end of week 24. The course was largely parallel for both
ADHD subtypes (Figure 3a). Over the entire time period,
patients of the combined subtype had significantly higher
scores than patients of the predominantly inattentive sub-
type (combined subtype, baseline: 32.4 [30.2 to 34.5],
week 2: 19.8 [17.3 to 22.3], week 8: 15.4 [13.0 to 17.9],
week 24: 15.7 [13.2 to 18.2], predominantly inattentive
subtype, baseline: 24.3 [22.4 to 26.3], week 2: 13.4 [11.4
to 15.4], week 8: 10.3 [8.8 to 11.8], week 24: 11.1 [9.1 to
13.1]).
Looking at the ADHD-RS sub-scores, courses of the
Hyperactivity-Impulsivity and Inattention sub-scores fol-
lowed the general pattern shown for the total score. Com-
bined subtype of ADHD was again associated with
statistically significantly higher mean scores than the pre-
dominantly inattentive subtype, this held for the Hyperac-
tivity-Impulsivity subscore but not the Inattention
subscore (Figures 3b and 3c).
Clinical Global Impression (CGI-S)
The mean CGI-S-ADHD score (LOCF) for the overall sam-
ple significantly decreased from 4.8 [95%CI 4.7 to 5.0] at
baseline to 3.4 [3.2 to 3.6] at week 8 and stayed stable
thereafter until week 24 (3.3 [3.1 to 3.5]). Regarding the
ADHD-subtypes, a comparable decrease was observed.
The mean CGI-S-ADHD scores of the predominantly inat-
tentive subtype tended to be slightly lower than the scores
of the combined type over the entire course of the study,
but the differences did not reach statistical significance
(Figure 4).
Tolerability
Investigators reported treatment emergent adverse events
in 124 (78.0%) patients over the entire study period.
Adverse events reported in more than 5% of all patientsChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
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GIPD total (a), morning (b) and evening (c) scores, as rated by patients, parents and physicians (OC analysis) Figure 2
GIPD total (a), morning (b) and evening (c) scores, as rated by patients, parents and physicians (OC analysis).
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Table 3: GIPD morning scores, rated by patients, parents and physicians, by ADHD subtype
GIPD morning score
Patient rated Parent rated Physician rated
ADHD subtype N Mean 95% CI N Mean 95% CI N Mean 95% CI
All
Week 0 158 2.5 2.3 – 2.8 157 3.1 2.8 – 3.4 158 3.3 3.1 – 3.5
Week 2 157 2.1 1.9 – 2.3 148 2.2 2.0 – 2.5 158 2.3 2.1 – 2.5
Week 8 158 2.0 1.8 – 2.2 150 2.1 1.9 – 2.3 158 1.9 1.7 – 2.1
Week 24 158 1.9 1.7 – 2.2 153 2.1 1.9 – 2.4 158 2.2 2.0 – 2.4
Combined type
Week 0 80 2.6 2.2 – 2.9 80 3.2 2.8 – 3.6 80 3.4 3.1 – 3.7
Week 2 80 2.2 1.8 – 2.6 76 2.4 2.1 – 2.7 81 2.5 2.2 – 2.7
Week 8 81 2.1 1.8 – 2.4 77 2.2 1.9 – 2.5 81 2.2 1.9 – 2.5
Week 24 81 2.0 1.7 – 2.4 77 2.2 1.9 – 2.5 81 2.4 2.1 – 2.7
Predominantly inattentive type
Week 0 73 2.5 2.1 – 2.8 72 3.0 2.6 – 3.4 73 3.2 2.9 – 3.6
Week 2 72 2.0 1.7 – 2.3 67 2.1 1.8 – 2.3 72 2.1 1.8 – 2.3
Week 8 72 1.8 1.5 – 2.1 68 2.0 1.7 – 2.3 72 1.7 1.4 – 1.9
Week 24 72 1.8 1.5 – 2.1 71 2.1 1.7 – 2.4 72 2.0 1.7 – 2.3
Patient and physician ratings based on LOCF (Last Observation Carried Forward), parent ratings are for LOCF-BR (LOCF, Baseline Rater:
Values not rated by the same individual both at baseline and later on (e. g., father rated at baseline, mother rated later) were replaced by the last 
value from the baseline rater (if present), otherwise the value was deleted.
CI = Confidence Interval
Table 4: GIPD evening scores, rated by patients, parents and physicians, by ADHD subtype
GIPD evening score
Patient rated Parent rated Physician-rated
ADHD subtype N Mean 95% CI N Mean 95% CI N Mean 95% CI
All
Week 0 158 2.2 2.0 – 2.4 158 3.5 3.3 – 3.7 158 3.9 3.6 – 4.1
Week 2 158 1.9 1.7 – 2.1 149 2.6 2.3 – 2.8 158 2.5 2.3 – 2.7
Week 8 158 1.8 1.6 – 2.0 150 2.2 2.0 – 2.4 158 2.2 2.0 – 2.4
Week 24 158 1.9 1.7 – 2.1 153 2.3 2.1 – 2.6 158 2.4 2.2 – 2.7
Combined type
Week 0 80 2.4 2.0 – 2.7 80 3.7 3.4 – 4.1 80 4.2 3.8 – 4.5
Week 2 81 2.1 1.8 – 2.4 77 2.9 2.5 – 3.2 81 2.8 2.5 – 3.1
Week 8 81 1.9 1.7 – 2.2 77 2.4 2.1 – 2.7 81 2.5 2.2 – 2.9
Week 24 81 1.9 1.6 – 2.2 77 2.4 2.0 – 2.7 81 2.6 2.3 – 3.0
Predominantly inattentive type
Week 0 73 2.1 1.7 – 2.4 73 3.3 2.9 – 3.6 73 3.5 3.2 – 3.9
Week 2 72 1.8 1.5 – 2.0 67 2.3 1.9 – 2.6 72 2.1 1.9 – 2.4
Week 8 72 1.7 1.4 – 2.0 68 2.1 1.8 – 2.4 72 1.9 1.6 – 2.1
Week 24 72 1.8 1.5 – 2.1 71 2.4 2.1 – 2.7 72 2.2 1.9 – 2.6
Patient and physician ratings based on LOCF (Last Observation Carried Forward), parent ratings are for LOCF-BR (LOCF, Baseline Rater:
Values not rated by the same individual both at baseline and later on (e. g., father rated at baseline, mother rated later) were replaced by the last 
value from the baseline rater (if present), otherwise the value was deleted.
CI = Confidence IntervalChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
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(N = 159) were: fatigue 45 (28.3%), headache 38
(23.9%), nausea 30 (18.9%), nasopharyngitis 21
(13.2%), vomiting 21 (13.2%), upper abdominal pain 12
(7.5%), decreased appetite 12 (7.5%), dizziness 12
(7.5%), diarrhea 9 (5.7%). In 82 (51.6%) patients the
investigators considered the adverse event as possibly
related to atomoxetine. Adverse events reported in more
than 5% of the patients and rated as possibly related to
atomoxetine were: fatigue (N = 42, 26.2%), nausea (N =
22, 13.8%), headache (N = 15, 9.4%), upper abdominal
pain (N = 11, 6.9%), decreased appetite (N = 11, 6.9%),
dizziness 9 (5.7%) and vomiting 9 (5.7%). There were 8
patients with serious adverse events, which were consid-
ered related to atomoxetine in two patients (1 patient with
severe vomiting; 1 patient with abdominal pain, dissocia-
tion, disturbance in attention, dizziness, fatigue and
peripheral vasoconstriction with dark, marbled skin).
Treatment-emergent adverse events led to discontinuation
in 7 (4.4%) patients: alopecia, decreased appetite, drug
abuse (acute intoxication with unknown medication plus
alcohol, hospitalized at emergency unit, then at inpatient
adolescent psychiatry ward) fatigue, vasoconstriction
(patient above, with additional symptoms/events, hospi-
talized for diagnostic process), vertigo and vomiting in 1
(0.6%) patient each. Except for fatigue and drug abuse, all
these adverse events were rated as possibly related to treat-
ment.
Mean laboratory parameters, including liver function
tests, were found within normal ranges with only minor
fluctuations over the course of the study (observed cases;
ALT: BL 19 ± 8 U/L; wk 8, 18 ± 9; wk 24, 17 ± 7. AST: BL
28.0 ± 6 U/L; wk 8, 28 ± 9, week 24, 26 ± 5). For vital
signs, increases in systolic and diastolic blood pressure
(SBP, DBP) and heart rate were observed as: SBP: BL,
112.6 ± 13.9 mmHg; wk 8, 115.4 ± 12.9, wk 24, 117.5 ±
12.1. DBP: BL, 70.3 ± 10.0 mmHg; wk 8, 72.8 ± 8.8; wk
24, 73.8 ± 9.2. Heart rate: BL, 77.9 ± 10.7 bpm; wk 8, 87.1
± 13.6; week 24, 84.8 ± 12.0.
Discussion
To our knowledge, this is the largest single study focusing
on adolescent ADHD patients treated with atomoxetine
[18,19]: 159 adolescent patients with ADHD according to
DSM-IV-TR were included in this open-label trial with ato-
moxetine in Germany. The retention rate over the 24-
week course of the study was 69.8%, a result closely
resembling the 6-month retention rate of 64.9% reported
by Perwien et al. from an atomoxetine study in N = 912
patients aged 6–17 years [30]. Patients in this trial were
treated with atomoxetine at a mean dose very close to the
target dose recommended in the summary of product
characteristics (SPC). The rates of psychiatric comorbidi-
ties were low compared to studies performed in children.
And, interestingly, there was a more than 5-year time win-
dow between first occurrence of symptoms and profes-
Table 5: Agreement (Cohen's Kappa coefficients) between patient-, parent- and physician rated GIPD total scores, by ADHD subtype
Agreement between
Physician and parent Patient and parent Patient and physician
ADHD subtype N Kappa 95% CI N Kappa 95% CI N Kappa 95% CI
All
Week 0 153 0.533 0.451 – 0.615 153 0.221 0.132 – 0.310 154 0.186 0.112 – 0.259
Week 2 128 0.550 0.460 – 0.641 127 0.359 0.257 – 0.461 147 0.391 0.294 – 0.489
Week 8 112 0.538 0.443 – 0.633 111 0.318 0.205 – 0.432 126 0.385 0.284 – 0.485
Week 24 104 0.639 0.552 – 0.725 103 0.363 0.255 – 0.471 111 0.425 0.319 – 0.532
Combined type
Week 0 79 0.504 0.382 – 0.626 78 0.155 0.041 – 0.270 78 0.131 0.045 – 0.216
Week 2 68 0.509 0.375 – 0.644 67 0.313 0.184 – 0.442 74 0.411 0.287 – 0.534
Week 8 61 0.454 0.306 – 0.602 62 0.222 0.081 – 0.362 66 0.347 0.209 – 0.484
Week 24 55 0.662 0.529 – 0.795 55 0.382 0.237 – 0.527 57 0.402 0.267 – 0.536
Predom. inattentive type
Week 0 69 0.551 0.439 – 0.663 70 0.280 0.142 – 0.419 71 0.237 0.113 – 0.360
Week 2 55 0.556 0.437 – 0.674 55 0.399 0.235 – 0.562 68 0.339 0.190 – 0.489
Week 8 48 0.631 0.511 – 0.751 46 0.434 0.250 – 0.619 56 0.419 0.270 – 0.568
Week 24 45 0.609 0.499 – 0.720 44 0.320 0.159 – 0.481 50 0.438 0.263 – 0.613
Patient and physician ratings based on LOCF (Last Observation Carried Forward), parent ratings are for LOCF-BR (LOCF, Baseline Rater: Values 
not rated by the same individual both at baseline and later on (e. g., father rated at baseline, mother rated later) were replaced by the last value 
from the baseline rater (if present), otherwise the value was deleted.
CI = Confidence IntervalChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
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ADHD Rating Scale (ADHD-RS-Par:Inv), a) total score, b) hyperactivity-impulsivity subscore, c) inattention subscore (for all  patients and by ADHD subtype, OC analysis) Figure 3
ADHD Rating Scale (ADHD-RS-Par:Inv), a) total score, b) hyperactivity-impulsivity subscore, c) inattention 
subscore (for all patients and by ADHD subtype, OC analysis).
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sional diagnosis, approximately 2 years longer than
observed, e. g., in the child study conducted in parallel
[37].
As the primary objective, we investigated possible differ-
ences in perceptions of ADHD-related difficulties by
patients, parents, and physicians using the recently
devised GIPD instrument [36]. In evaluating the respec-
tive findings it has to be pointed out that GIPD instru-
ment and CGI-S scale – although similar in the wording
and format of a 7-point Likert scale – should not be seen
as fully analogue. While the investigator assesses CGI-S in
comparison to the group of patients with the same disor-
der [cf. instructions; [23,24]], GIPD ratings by the three
different raters are to be done without that reference.
Thus, GIPD baseline mean values and changes over time
may not be understood and interpreted in the same way.
When considering discriminant validity in the recent vali-
dation paper [36] (including data from this sample), a
monotone but non-linear increase was observed when
relating GIPD total scores to the CGI-S levels. In compar-
ison to physician and parent ratings, patient-rated GIPD
total scores increased to a much lower degree with increas-
ing CGI-S scores.
In this study with adolescent ADHD patients, the degree
of the ADHD-related difficulties was rated statistically sig-
nificantly lower by the patients than by their parents or
their physicians. In contrast, the difference between the
parent and physician GIPD ratings was small. With refer-
ence to the methodological approach chosen in this trial,
it appeared that these patients subjectively perceived the
degree of their ADHD-related difficulties as lower than
their parents or physicians did. These findings were con-
sistent with the parallel open-label study in children with
ADHD [37], as well as with the recent double-blind study
in children and adolescents [10].
Interestingly, the baseline self-reports of adolescent
ADHD patients with the combined subtype vs. the pre-
dominantly inattentive subtype did not differ as to the
severity of perceived ADHD-related difficulties. In con-
trast, parents and physicians rated the difficulties of the
patients with the combined type as slightly more severe
(n. s.) than those of the patients with the predominantly
inattentive type, potentially corresponding to the clinical
observation of third-party raters' assessing the impact of
inattention as less burdensome.
Clinical Global Impression – Severity (CGI-S-ADHD), for all patients and by ADHD subtype (OC analysis) Figure 4
Clinical Global Impression – Severity (CGI-S-ADHD), for all patients and by ADHD subtype (OC analysis).
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The differences between the three perspectives persisted
over the entire observation period. At the end of the acute
treatment period (week 8), GIPD Total scores were statis-
tically significantly reduced for all three rater groups
(mean change from baseline: patients -2.9, -23.2%, par-
ents -5.9, -34.3%, physicians -7.8, -41.5%), This level of
improvement persisted until week 24. In general, these
findings also held for the single-item GIPD evening and
morning assessments. This statistically significant and
consistent decline in ADHD-related difficulties during
atomoxetine treatment may cautiously be interpreted to
reflect an improvement in patient overall impairment,
social functioning, and QoL in this adolescent patient
population. Again, findings were highly consistent with
the parallel study in children [37]. In addition, a second-
ary analysis of pooled data from both studies showed
improvements in emotional well-being as measured by
ten specific items from the Pediatric Adverse Event Rating
Scale (PAERS) [41,42]. To evaluate the clinical signifi-
cance and daily-life impact of these GIPD changes, further
investigation will be needed, under controlled conditions,
potentially studying additional outcome parameters, pop-
ulations, and/or comparator compounds.
Previous studies that used more specific instruments to
assess QoL in children and adolescents with ADHD
[8,10,14,28-30,43], such as the Child Health Question-
naire (CHQ) [25] or the Child Health Illness Profile
(CHIP) [10,26], had reported similar findings. For exam-
ple, Klassen et al. [32] and Riley et al. [6] observed health-
related QoL scores of young ADHD patients of up to two
standard deviations below population norms reflecting
marked impairments. Further, a recent double-blind, pla-
cebo controlled 12-week study of atomoxetine treatment
in 151 children and adolescents aged 6–15 years also
found that HRQoL, as assessed by parents and patients
using the CHIP instrument, improved during atomoxet-
ine treatment [10]. Patient-rated QoL impairment was less
severe than parent-rated impairment, and correlation
between QoL ratings (CHIP) and clinical disease severity
(ADHD-RS) was lower for patients' than for parents' [10].
As summarized by Steele et al. [45], studies with sus-
tained-release formulations of stimulants also found
ADHD symptom reduction and improvement in func-
tional outcomes, e.g. in measures of social play and paren-
tal stress, fewer accidents and injuries, better driving
performance and fewer general practitioner visits.
Cohen's Kappa coefficients varied considerably across the
three rater groups and the course of the study, with strong-
est (moderate) agreements between physician and parent
assessments, and significant improvements of patient/
physician agreements over time. Study design features,
with choosing a nearly naturalistic sequence of applying
instruments and using information as in an office-setting,
may have impacted on this outcome.
With respect to the secondary objectives of this study,
mean ADHD-RS Total scores decreased statistically signif-
icantly over time, with -15.6 (-54.9%) mean change, from
a relatively low baseline (28.4) to week 8 (12.9) in this
adolescent population. Wilens et al. [18] reported related
findings from a meta-analysis of six placebo-controlled
acute studies) with an ADHD-RS baseline score of 36.3,
and -38.5% mean change to endpoint. The high rate of
45.9% adolescent patients with predominantly inatten-
tive ADHD-subtype in our study sample may have con-
tributed to the low mean baseline score and the high
relative change in ADHD symptoms for the entire sample.
Very similar results as here were derived from another
meta-analysis by Wilens et al. based on 13 long-term ato-
moxetine studies with adolescent ADHD patients [19]:
ADHD-RS baseline score 34.7, and -58.2% mean change
to endpoint. Finally, an analysis from seven placebo-con-
trolled trials by Adler et al. showed significantly larger
treatment effects in adolescents vs. adults (baseline
ADHD-RS score 37.3) [20].
The percentage of ADHD-RS mean change for adolescents
reported here was generally in line with several placebo-
controlled trials – involving both children and adoles-
cents – which showed efficacy with atomoxetine treat-
ment [8,13-15]. In these double-blind studies (1.2 mg/kg/
d arm from Michelson et al., 2001 [8]), e.g., mean ages
ranged from 9.7 to 11.5 years, baseline mean ADHD-RS
scores from 37.6 to 42.1, and % mean changes from -34.0
to -39.7%. The respective values from our open-label
study performed in children (N = 262; 6 to 11 years) were:
9.3 years, 35.2, and -38.9% [37].The current findings sup-
port the notion that treatment with atomoxetine is effec-
tive, since symptom reductions in these open-label studies
were similar to those in randomized, placebo-controlled
trials, with certain differences for the child and adolescent
populations. They may also suggest that open-label study
results do not necessarily reflect observer bias towards
higher effectiveness compared to double-blind placebo-
controlled trials.
Based on ADHD-RS assessments, effectiveness was shown
both for the combined type and the predominantly inat-
tentive type of ADHD. This finding could be anticipated
since atomoxetine has been known to improve both
hyperactive/impulsive and inattentive symptoms of
ADHD [8,13,15,44]. The ADHD-RS total score at baseline
was significantly higher in patients with combined type
ADHD than in patients with predominantly inattentive
type ADHD, as to be expected. Furthermore, in this study,
the baseline mean ADHD-RS total score in girls was
observed to be below the ratings for boys. Some reportsChild and Adolescent Psychiatry and Mental Health 2009, 3:21 http://www.capmh.com/content/3/1/21
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indicate that core ADHD symptoms observed in girls are
similar to those seen in boys with ADHD [16,46]. But
there are also findings that girls with ADHD appear to be
less hyperactive-impulsive and thus possibly less
impaired than boys [47].
Mean CGI-S scores also significantly improved over time
[cf. [8,13,15]], this applied both to the group with com-
bined type ADHD and to the group with predominantly
inattentive type ADHD. CGI-S scores in patients with
combined type ADHD were reported above that in
patients with predominantly inattentive type ADHD.
Together with the results from the ADHD-RS these find-
ings seem to support the notion that the subtype of
ADHD may to some extent be a reflection of overall
ADHD severity. This has also been suggested for comor-
bid oppositional defiant disorder (ODD) which may also
reflect overall ADHD severity [44].
In general, the pattern of treatment-emergent adverse
events in this study appeared to be in line with that
reported in randomized, placebo-controlled trials in chil-
dren [13,15,16] or children and adolescents [8], respec-
tively. Compared to these studies, only the rates of fatigue
and nausea were relatively high. This may reflect a differ-
ent pattern of physical complaints and adverse events in
an adolescent population, or be due to the open-label
design of this study. Changes in laboratory parameters
and vital signs were not considered clinically relevant.
The reported data from this study should be interpreted
cautiously in the context of its methodological limita-
tions: The open-label study design in general is prone to
rater bias, although symptom improvements over time
were corresponding to results from double-blind placebo-
controlled trials. And, as often observed when using sev-
eral instruments, there will be overlap in constructs meas-
ured by the various scales [9]. The sequence of applying
the scales and instruments in this study may also have
influenced the investigator GIPD ratings and, thus, the
Cohen's Kappa values indicating moderate parent/physi-
cian agreement. In the absence of comparator groups
(e.g., placebo, somatic or other mental disorders) findings
remain open to interpretation. In retrospect, it has also to
be acknowledged that our study design and the data as
collected did not allow to explore and investigate further
the clinical and practical relevance of the differences
observed between raters. Issues related to actual impair-
ment and QoL as well as potential impact for differential
approaches in psycho-education and treatment of ADHD,
both in adolescents and parents, certainly appear to be of
great importance. Further, reporting of adverse events may
to some degree depend on the timing of the study with
respect to the life cycle of a compound; e.g., physicians'
experience and perspectives, and thus reporting rates may
change with several years of using a medication after mar-
ket introduction [48,49].
In summary, adolescent patients rated their ADHD-
related difficulties, which can be considered to reflect
overall impairment, social functioning, and QoL, as lower
than either parents or physicians did. All three rater
groups reported clear reductions in severity of these per-
ceived difficulties over time, for total, evening, and morn-
ing assessments. The different views, the patient
perspective on daily difficulties in particular, may provide
important additional information when evaluating effec-
tiveness of a treatment [cf [36]] and adjusting compo-
nents of therapy individually. ADHD core symptoms also
improved over the course of treatment, and atomoxetine
was generally well tolerated.
The reported differences in overall GIPD ratings and their
statistical relevance may guide clinicians and researchers
to collect more detailed differential data on actual impair-
ment and quality of life from both adolescent ADHD
patients and their parents, if applying more elaborate
techniques and measures, both in clinical work and in
future studies focussing on HRQoL. Additionally, com-
parative research is needed on the impact of various
ADHD medications, focusing not only on the core symp-
toms of ADHD but as well on the health-related quality of
life and functional outcomes of both patients and fami-
lies, considering age and gender effects across the life-
span.
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